84 results on '"Bayik, M."'
Search Results
2. Behçet's disease in patients with chronic myelogenous leukemia: possible role of interferon-alpha treatment in the occurrence of Behçet's symptoms
- Author
-
Budak-Alpdoğan, T., Demirçay, Z., Alpdoğan, Ö., Direskeneli, H., Ergun, T., Bayik, M., and Akoğlu, T.
- Published
- 1997
- Full Text
- View/download PDF
3. BLOOD BANKING IN DISASTERS AND EMERGENCIES: 1ED-01--8
- Author
-
Bayik, M
- Published
- 2007
4. Standardizing the method of infusion of stem cells during autologous stem cell transplantation in a university hospital, Istanbul, Turkey
- Author
-
Erdal, S., Birtas Atesoglu, E., Kulaksiz, Y., Engyn, P., Gülen, Z., Ataman, G., and Bayik, M.
- Published
- 2007
5. QUALITY OF LEUKOCYTE REMOVAL FILTERS USED IN MARMARA UNIVERSITY HOSPITAL BONE MARROW TRANSPLANTATION UNIT: P-477
- Author
-
Erdal, S., Atesoglu, E. Birtas, Kaygysuz, I., Aktas, S., Noyan, F., Adiguzel, C., Engin, P., Gulen, Z., Sisman, S., Ataman, G., Yaman, G., Cetiner, M., Tuglular, T. Firalati, and Bayik, M.
- Published
- 2006
6. Effects of a major earthquake on blood donor types and infectious diseases marker rates
- Author
-
Sönmezoglu, M., Kocak, N., Öncul, O., Özbayburtlu, S., Hepgul, Z., Kosan, E., Aksu, Y., and Bayik, M.
- Published
- 2005
7. Quality of life assessment of haematopoietic stem cell transplantation patients in Istanbul: a pilot study
- Author
-
Çetiner, M., Kalaça, S., Ratip, S., Yazgan, Ç., Adigüzel, C., Kalayoglu-Besisik, S., Argon, D., Kaygusuz, I., Aktuglu, G., and Bayik, M.
- Published
- 2004
8. Scleredema of Buschke associated with Waldenström's macroglobulinaemia
- Author
-
Ratip, S., Akin, H., Özdemirli, M., Yücelten, D., Kuş, S., Ekenel, M., and Bayik, M.
- Published
- 2000
9. Clinical microbiological case: chronic disseminated candidiasis unresponsive to treatment
- Author
-
Ratip, S., Odabaşi, Z., Karti, S., Çetiner, M., Yeğen, C., Çerikcioğlu, N., Bayik, M., and Korten, V.
- Published
- 2002
- Full Text
- View/download PDF
10. Bone marrow transplantation data for marmara university school of medicine: 1989-1998
- Author
-
Cetiner, M., Ratip, S., Ovali, E., Karti, S., Bayik, M., and Akoglu, T.
- Subjects
surgical procedures, operative ,Bone marrow transplantation,allogeneic,autologous,peripheral blood stem cell ,Medicine ,Tıp - Abstract
Objectives: The aim of this study was to analyse the bone marrow transplantation data at the Haematology Department of Marmara University Hospital between 1989 and 1998.Methods: The transplant data and survival of 56 patients, who had allogeneic (n=42) or autologous (n=14) bone marrow transplantation, were evaluated retrospectively.Results: The most common complicationsencountered in bone marrow transplant patients were infections and graft versus host disease (GVHD). The primary causes of death were acute and chronic GVHD. Chronic GVHD was significantly higher in the allogeneic peripheral stem cell transplantation (Allo- PBSCT) in comparison with allogeneic bone marrow transplantation (Allo-BMT) .Disease free survival for allo-BMT, allo-PBSCT, and autologous PBSCT was 61.2%, 54,5% and 30.7% respectively, Transplant related mortality in allo-BMT, and allo-PBSCT was 32.2%, and 36.3% respectively. Disease free survival in acute myeloid leukaemia and acute lymphocytic leukaemia patients were 70.5% and 66.6% respectively at median 3.5 years follow up.Conclusion: Bone marrow transplantation at Marmara University Hospital has survival data in line with the tranplantation units of most Western countries. The number of transplants is expected to rise in the future provided better conditions are established for maintenance and expansion of the transplant centre
- Published
- 2016
11. Genotype phenotype relationships in beta thalassaemias
- Author
-
RATİP, S., BAYİK, M., and AKOGLU, T.
- Subjects
congenital, hereditary, and neonatal diseases and abnormalities ,hemic and lymphatic diseases ,Medicine ,Thalassaemia major,Thalassaemia intermedia,genotype,phenotype ,Tıp - Abstract
The homozygous state for B-thalassaemia usually results In thalassaemia major, which requires monthy blood transfusions and regular infusions of the iron chelating agent desferrioxamine, for life. Some patients are less severely affected and survive either with no blood transfusion or without regular blood transfusion. This milder syndrome is termed thalassaemia intermedia. A significant amount of genetic information is now available in order to predict the thalassaemia intermedia phenotype from the genotype. Important ameliorating genetic factors are mild p-thalassaemia mutations, co-inheritance of a- thalassaemia, and presence of polymorphisms adjacent to the (3-globin gene complex or mutations that increase HbF production by enhancing gamma- globin chain production. Accurate and precise prediction of phenotype from genotype will have important implications for prenatal diagnosis. Early diagnosis of thalassaemia intermedia is also important in order to avoid treatment with regular blood transfusions as for thalassaemia major, since a significant part of the morbidity and mortality arises from iron overload due to regular transfusion.
- Published
- 2016
12. The effect of lymphoid antigen expression on prognosis of the patients with acute myeloblastic leukemia
- Author
-
ALPDOĞAN, Ö., DEMİRALP, D., AKOĞLU, T., and BAYIK, M.
- Subjects
hemic and lymphatic diseases ,Medicine ,Acute myeloblastic leukemia,lymphoid associated antigens,T lymphocyte associated antigens,B lymphocyte associated antigens ,Tıp - Abstract
Objective: Lymphoid antigen expression is very common in patients with acute myeloblastic leukemia (AML), but the predictive value of lymphoid antigen expression on the prognosis of AML remains unclear. In this study we tried to find out the effect of lymphoid antigen expression on prognosis of the patients with acute myeloblastic leukemia.Methods: Seventy patients with AML, admitted to Marmara University Hospital between January 1989 and December 1995, were analyzed for blast cell lymphoid antigen expression, and prognosis. Lymphoid antigens examined on the myeloblasts were CD2, CD3, CD7, CD10 and CD19.Results: Twenty-four patients (34.2%) had one or more positive lymphoid antigens present in their blasts. Six patients had T lymphoid associated antigen (8.5%), 12 patients had B lymphoid associated antigen (17.1%) and six patients had both B and T lymphoid antigens (8.5%). No differences were found between lymphoid marker positive and negative groups in terms of age, leukocyte count on admission, serum LDH levels, complete remission rate, relapse rate and survival. Four out of six patients (67%) expressing both T and B lymphoid antigens died within the first month of the diagnosis. The early mortality rate of this group was different from the patients whose blasts expressed T or B lymphoid antigens alone (67% v 11% p
- Published
- 2016
13. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow
- Author
-
Gorin N.C., Labopin M., Rocha V., Arcese W., Beksac M., Gluckman E., Ringden O., Ruutu T., Reiffers J., Bandini G., Falda M., Zikos P., Willemze R., Frassoni F., Abecasis M., Abráhamová J., Afanassiev B.V., Aglietta M., Alabdulaaly A., Aleinikova O., Paolo Alessandrino E., Al Shemmari S.H., Amadori D., Amadori S., Amos T., Andolina M., Andreesen R., Angelucci E., Anhuf J., Arnold R., Arpaci F., Attal M., Azevedo W., Azim H.A., Baccarani M., Bacigalupo A., Barbui T., Bargetzi M., Barnard D.L., Bartsch H.H., Baruchel A., Battista C., Bay J.-O., Bayik M., Bazarbachi A., Beguin Y., López J.L.B., Benedek I., Benedetti F., Bengala C., Berrebi A., Besalduch J., Biesma D., Biron P., Björkholm M., Blaise D., Blesing N.E., Boasson M., Bobev D., Boccadoro M., Bolaman Z., Boogaerts M.A., Bordessoule D., Bosi A., Aida B.S., Bourhis J.H., Bourikas G., Bowen D.T., Bregni M., Bries G., Brinch L., Brittain D., Bron D., Brune M., Bullorsky E.O., Bunjes D., Burdach S., Burnett A.K., Buzyn A., Caballero D., Cagirgan S., Cahn J.-Y., Canepa C.O., Cao A., Carella A.M., Carrera F.D., Carret A.-S., Cascinu S., Castel V., Caswell M., Cavanna L., Cetto G.L., Chapuis B., Chasty R., Chen Y.-C., Chisesi T., Chopra R., Chybicka A., Clark R.E., Colombat P., Colovic M.D., Constenla-Figueiras M., Contreras M., Contu L., Cordonnier C., Cornelissen J.J., Cornish J., Coser P., Costa N., Coze C., Craddock C., Crown J., Culligan D.J., Danova M., Darbyshire P.J., Davies J.M., de Bock R., de Pablos Gallego J.M., De Prijck B., de Revel T., De Rossi G., De Souza C.A., Deb G., Degos L., Demuynck H., Dervenoulas I., Di Bartolomeo P., Di Renzo N., Diaz M.A., Diehl V., Diez-Martin J.L., Dincer S., Giorgio D., Dmoszynska A., Doelken G., Peter P.D., Dulley F., Easow J., Ebell W., Efremidis A., Ehninger G., Eichler H., Eimermacher H., Enno A., Errazquin L., Aguado J.E., Everaus H., Fagioli F., Fanin R., Fassas A., Fasth A., Faulkner L.B., Fauser A.A., Feldman L., Feremans W., Ferhanoglu B., Fernández M.N., Fernández-Ranada J.M., Ferrant A., Ferrara F., Finke J., Fischer A., Fischer J., Fitzsimons T., Floristan F., Forjaz de Lacerda J.M.F., Fossati-Bellani F., Fosser V., Franklin I., Freund M., Frickhofen N., Gabbas A., Gadner H., Gallamini A., Galvin M.C., López J.G., García-Conde J., Gaska T., Gastl G., Gedikoglu G., Ghavamzadeh A., Gianni A., Gibson B.E., Gil J.L., Gilleece M.H., Gisselbrecht C., Glass B., Gmür J., Göbel U., Goldman J.M., Goldstone A.H., San Miguel J.D.G., González-López M.-A., Grafakos S., Gramatzki M., Grañena A., Gratecos N., Gratwohl A., Greinix H.T., Gugliotta L., Guilhot F., Guimaraes J.E., Gülbas Z., Gulyuz O., Gurman G., Gutierrez M.M., Haas R., Hamladji R.-M., Hamon M.D., Hansen N.E., Harhalakis N., Harousseau J.L., Hartenstein R., Hartmann C.O., Hausmaninger H., Haznedar R., Heit W., Hellmann A., Herrmann R.P., Hertenstein B., Hess U., Hinterberger W., Ho A.D., Hoelzer D., Holowiecki J., Horst H.-A., Hossfeld D.K., Huebsch L., Hunter A.E., Iacopino P., Iannitto E., Indrák K., Iriondo A., Izzi T., Jackson G.L., Jacobs P., Jacobsen N., Janvier M., Jebavy L., Joensuu H., Joerg S., Jones F.G.C., Jouet J.P., Joyner M.V., Juliusson G., Jürgens H., Kalayoglu-Besisik S., Kalman N., Kalmanti M., Kansoy S., Kansu E., Kanz L., Karianakis G., Kernéis Y., Khalifeh O., Khomenko V., Kienast J., Killick S., Kirchner H.H., Klingebiel T., Knauf W., Koenigsmann M., Koistinen P., Koivunen E., Kolb H.-J., Kolbe K., Koller E., Komarnicki M., Koscielniak E., Kovacsovics T., Kowalczyk J.R., Koza V., Kozak T., Kugler J., Kuliczkowski K., Kvaloy S., Labar B., Laciura P., Palacios J.J.L., Lakota J., Lambertenghi D.G., Lange A., Lanza F., Isasti R.L., Lauria F., Le Moine F., Leblond V., Lelli G., Lenhoff S., Leon L.A., Leoncini-Franscini L., Leone G., Leoni P., Levis A., Leyvraz S., Liberati M., Link H., Linkesch W., Liso V., Lisukov I.A., Littlewood T., Ljungman P., Locatelli F., Losonczy H., Lotz J.-P., Ludwig H., Lukac J., Lutz D., Macchia P., Madrigal A., Maiolino A., Majolino I., Eloy-García J.M., Malesevic M., Mandelli F., Marc A., Marcus R., Marianska B., Markuljak I., Marsh J.C.W., Martelli M.F., Marti Tutusaus J.M., Martin S., Martin M., Martinelli G., Martínez-Rubio A.M., Martoni A., Maschan A., Maschmeyer G., Masszi T., Mazza P., McCann S., Meier C.R., Messina C., Mettivier V., Metzner B., Michallet M., Michieli M., Michon J., Milligan D.W., Milone J.H., Giuseppe G.M., Minigo H., Mistrik M., Moicean A.D., Monfardini S., Montserrat E., Moraleda Jimenez J.M., Morales-Lazaro A., Morandi S., Morra E., Mufti G.J., Musso M., Nagler A., Nalli G., Naparstek E., Narni F., Nenadov-Beck M., Neubauer A., Newland A.C., Niederwieser D., Niethammer D., Noens L.A., Nousiainen T., Novik A., Novitzky N., Occhini D., Odriozolas J., Ojanguren J.M., O’meara A., Onat H., Orchard K., Ortega J.J., Osieka R., Ossenkoppele G.J., Othman B., Ovali E., Ozcebe O.I., Ozerkan K., Ozturk A., Papatryfonos A., Parker J.E., Pastore M., Patrone F., Patton N., Pejin D., Peñarrubia M.J., Equiza E.P., Peschel C., Pession A., Pigaditou A., Pignon B., Pihkala U., Pimentel P., Pitini V., Podoltseva E., Pogliani E.M., Anna A.P., Porta F., Potter M., Powles R., Prentice G.H., Pretnar J., Ptushkin V., Quarta G., Reiter A., Remes K., Reykdal S., Santasusana J.M.R., Rifón J., Rio B., Rizzoli V., Robak T., Robinson A.J., Rodeghiero F., Rodríguez Fernández J.M., Rombos Y., Romeril K.R., Rosenmayr A., Rossi J.F., Rosti G., Rotoli B., Rowe J.M., Russell N.H., Ryzhak O., Rzepecki P., Saglio G., Salwender H., Samonigg H., Santoro A., Sanz M.A., Sayer H.G., Scanni A., Schaafsma M.R., Schaefer U.W., Schanz U., Schattenberg A., Schey S.A.M., Schlimok G., Schmoll H.-J., Schots R., Schouten H., Schwarer A.P., Schwerdtfeger R., Scimè R., Segel E., Seger R., Selleslag D., Serban M., Shamaa S., Shaw P.J., Siegert W., Siena S., Sierra J., Simonsson B., Singer C.R.J., Sirchia G., Skotnicki A.B., Slavin S., Snowden J., Sotto J.J., Tanyeli A., Tedeschi L., Tidefelt U., Tissot J.-D., Tobler A., Tomas J.F., Torres J.P., Torres G.A., Touraine J.-L., Trneny M., Uderzo C., Unal E., Unal A., Undar L., Urban C., Van den Berg H., van Marwijk K.M., Vellenga E., Venturini M., Verdonck L.F., Veys P., Vilardell J., Vinante O., Visani G., Vitek A., Vivancos P., Volpe E., Vora A., Vorlicek J., Vowels M., Vujic D., Wachowiak J., Wagner T., Wahlin A., Walewski J., Wandt H., Weissinger F., Wijermans P.W., Wiktor-Jedrzejczak W., Will A.M., Woell E., Wörmann B., Yaniv I., Yesilipek M.A., Yilmaz U., Yong A., Zachée P., Zambelli A., Zander A.R., Zintl F., Zoumbos N.C., Çukurova Üniversitesi, Maltepe Üniversitesi, and Ege Üniversitesi
- Subjects
Myeloid ,Male ,Pathology ,Time Factors ,Graft vs Host Disease ,Biochemistry ,Gastroenterology ,Blood cell ,Bone Marrow ,Child ,Bone Marrow Transplantation ,Leukemia ,Remission Induction ,Hematology ,Middle Aged ,Prognosis ,Leukemia, Myeloid, Acute ,ComputingMilieux_MANAGEMENTOFCOMPUTINGANDINFORMATIONSYSTEMS ,medicine.anatomical_structure ,Treatment Outcome ,Child, Preschool ,Female ,Stem cell ,InformationSystems_MISCELLANEOUS ,Homologous ,Adult ,medicine.medical_specialty ,Adolescent ,Immunology ,Acute ,Disease-Free Survival ,Internal medicine ,medicine ,Transplantation, Homologous ,Humans ,Preschool ,Aged ,Transplantation ,business.industry ,ComputerSystemsOrganization_COMPUTER-COMMUNICATIONNETWORKS ,Cell Biology ,medicine.disease ,Peripheral blood ,Histocompatibility ,Multivariate Analysis ,Stem Cell Transplantation ,ComputingMethodologies_PATTERNRECOGNITION ,Myelocytic leukemia ,Bone marrow ,business ,Settore MED/15 - Malattie del Sangue - Abstract
PubMed ID: 12829583, Several studies have compared bone marrow (BM) and peripheral blood (PB) as stem cell sources in patients receiving allografts, but the cell doses infused have not been considered, especially for BM. Using the ALWP/EBMT registry, we retrospectively studied 881 adult patients with acute myelocytic leukemia (AML), who received a non-T-depleted allogeneic BM (n = 515) or mobilized PB (n = 366) standard transplant, in first remission (CR1), from an HLA-identical sibling, over a 5-year period from January 1994. The BM cell dose ranged from 0.17 to 29 × 10 8 /kg with a median of 2.7 × 10 8 /kg. The PB cell dose ranged from 0.02 to 77 × 10 8 /kg with a median of 9.3 × 10 8 /kg. The median dose for patients receiving BM (2.7 × 10 8 /kg) gave the greatest discrimination. In multivariate analyses, high-dose BM compared to PB was associated with lower transplant-related mortality (RR = 0.61; 95% CI, 0.39-0.98; P = .04), better leukemia-free survival (RR = 0.65; 95% CI, 0.46-0.91; P = .013), and better overall survival (RR = 0.64; 95% CI, 0.44-0. 92; P = .016). The present study in patients with AML receiving allografts in first remission indicates a better outcome with BM as compared to PB, when the dose of BM infused is rich. © 2003 by The American Society of Hematology.
- Published
- 2003
14. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow
- Author
-
Gorin, N.C. Labopin, M. Rocha, V. Arcese, W. Beksac, M. Gluckman, E. Ringden, O. Ruutu, T. Reiffers, J. Bandini, G. Falda, M. Zikos, P. Willemze, R. Frassoni, F. Abecasis, M. Abráhamová, J. Afanassiev, B.V. Aglietta, M. Alabdulaaly, A. Aleinikova, O. Paolo Alessandrino, E. Al Shemmari, S.H. Amadori, D. Amadori, S. Amos, T. Andolina, M. Andreesen, R. Angelucci, E. Anhuf, J. Arnold, R. Arpaci, F. Attal, M. Azevedo, W. Azim, H.A. Baccarani, M. Bacigalupo, A. Barbui, T. Bargetzi, M. Barnard, D.L. Bartsch, H.H. Baruchel, A. Battista, C. Bay, J.-O. Bayik, M. Bazarbachi, A. Beguin, Y. López, J.L.B. Benedek, I. Benedetti, F. Bengala, C. Berrebi, A. Besalduch, J. Biesma, D. Biron, P. Björkholm, M. Blaise, D. Blesing, N.E. Boasson, M. Bobev, D. Boccadoro, M. Bolaman, Z. Boogaerts, M.A. Bordessoule, D. Bosi, A. Aida, B.S. Bourhis, J.H. Bourikas, G. Bowen, D.T. Bregni, M. Bries, G. Brinch, L. Brittain, D. Bron, D. Brune, M. Bullorsky, E.O. Bunjes, D. Burdach, S. Burnett, A.K. Buzyn, A. Caballero, D. Cagirgan, S. Cahn, J.-Y. Canepa, C.O. Cao, A. Carella, A.M. Carrera, F.D. Carret, A.-S. Cascinu, S. Castel, V. Caswell, M. Cavanna, L. Cetto, G.L. Chapuis, B. Chasty, R. Chen, Y.-C. Chisesi, T. Chopra, R. Chybicka, A. Clark, R.E. Colombat, P. Colovic, M.D. Constenla-Figueiras, M. Contreras, M. Contu, L. Cordonnier, C. Cornelissen, J.J. Cornish, J. Coser, P. Costa, N. Coze, C. Craddock, C. Crown, J. Culligan, D.J. Danova, M. Darbyshire, P.J. Davies, J.M. de Bock, R. de Pablos Gallego, J.M. De Prijck, B. de Revel, T. De Rossi, G. De Souza, C.A. Deb, G. Degos, L. Demuynck, H. Dervenoulas, I. Di Bartolomeo, P. Di Renzo, N. Diaz, M.A. Diehl, V. Diez-Martin, J.L. Dincer, S. Giorgio, D. Dmoszynska, A. Doelken, G. Peter, P.D. Dulley, F. Easow, J. Ebell, W. Efremidis, A. Ehninger, G. Eichler, H. Eimermacher, H. Enno, A. Errazquin, L. Aguado, J.E. Everaus, H. Fagioli, F. Fanin, R. Fassas, A. Fasth, A. Faulkner, L.B. Fauser, A.A. Feldman, L. Feremans, W. Ferhanoglu, B. Fernández, M.N. Fernández-Ranada, J.M. Ferrant, A. Ferrara, F. Finke, J. Fischer, A. Fischer, J. Fitzsimons, T. Floristan, F. Forjaz de Lacerda, J.M.F. Fossati-Bellani, F. Fosser, V. Franklin, I. Freund, M. Frickhofen, N. Gabbas, A. Gadner, H. Gallamini, A. Galvin, M.C. López, J.G. García-Conde, J. Gaska, T. Gastl, G. Gedikoglu, G. Ghavamzadeh, A. Gianni, A. Gibson, B.E. Gil, J.L. Gilleece, M.H. Gisselbrecht, C. Glass, B. Gmür, J. Göbel, U. Goldman, J.M. Goldstone, A.H. San Miguel, J.D.G. González-López, M.-A. Grafakos, S. Gramatzki, M. Grañena, A. Gratecos, N. Gratwohl, A. Greinix, H.T. Gugliotta, L. Guilhot, F. Guimaraes, J.E. Gülbas, Z. Gulyuz, O. Gurman, G. Gutierrez, M.M. Haas, R. Hamladji, R.-M. Hamon, M.D. Hansen, N.E. Harhalakis, N. Harousseau, J.L. Hartenstein, R. Hartmann, C.O. Hausmaninger, H. Haznedar, R. Heit, W. Hellmann, A. Herrmann, R.P. Hertenstein, B. Hess, U. Hinterberger, W. Ho, A.D. Hoelzer, D. Holowiecki, J. Horst, H.-A. Hossfeld, D.K. Huebsch, L. Hunter, A.E. Iacopino, P. Iannitto, E. Indrák, K. Iriondo, A. Izzi, T. Jackson, G.L. Jacobs, P. Jacobsen, N. Janvier, M. Jebavy, L. Joensuu, H. Joerg, S. Jones, F.G.C. Jouet, J.P. Joyner, M.V. Juliusson, G. Jürgens, H. Kalayoglu-Besisik, S. Kalman, N. Kalmanti, M. Kansoy, S. Kansu, E. Kanz, L. Karianakis, G. Kernéis, Y. Khalifeh, O. Khomenko, V. Kienast, J. Killick, S. Kirchner, H.H. Klingebiel, T. Knauf, W. Koenigsmann, M. Koistinen, P. Koivunen, E. Kolb, H.-J. Kolbe, K. Koller, E. Komarnicki, M. Koscielniak, E. Kovacsovics, T. Kowalczyk, J.R. Koza, V. Kozak, T. Kugler, J. Kuliczkowski, K. Kvaloy, S. Labar, B. Laciura, P. Palacios, J.J.L. Lakota, J. Lambertenghi, D.G. Lange, A. Lanza, F. Isasti, R.L. Lauria, F. Le Moine, F. Leblond, V. Lelli, G. Lenhoff, S. Leon, L.A. Leoncini-Franscini, L. Leone, G. Leoni, P. Levis, A. Leyvraz, S. Liberati, M. Link, H. Linkesch, W. Liso, V. Lisukov, I.A. Littlewood, T. Ljungman, P. Locatelli, F. Losonczy, H. Lotz, J.-P. Ludwig, H. Lukac, J. Lutz, D. Macchia, P. Madrigal, A. Maiolino, A. Majolino, I. Eloy-García, J.M. Malesevic, M. Mandelli, F. Marc, A. Marcus, R. Marianska, B. Markuljak, I. Marsh, J.C.W. Martelli, M.F. Marti Tutusaus, J.M. Martin, S. Martin, M. Martinelli, G. Martínez-Rubio, A.M. Martoni, A. Maschan, A. Maschmeyer, G. Masszi, T. Mazza, P. McCann, S. Meier, C.R. Messina, C. Mettivier, V. Metzner, B. Michallet, M. Michieli, M. Michon, J. Milligan, D.W. Milone, J.H. Giuseppe, G.M. Minigo, H. Mistrik, M. Moicean, A.D. Monfardini, S. Montserrat, E. Moraleda Jimenez, J.M. Morales-Lazaro, A. Morandi, S. Morra, E. Mufti, G.J. Musso, M. Nagler, A. Nalli, G. Naparstek, E. Narni, F. Nenadov-Beck, M. Neubauer, A. Newland, A.C. Niederwieser, D. Niethammer, D. Noens, L.A. Nousiainen, T. Novik, A. Novitzky, N. Occhini, D. Odriozolas, J. Ojanguren, J.M. O’meara, A. Onat, H. Orchard, K. Ortega, J.J. Osieka, R. Ossenkoppele, G.J. Othman, B. Ovali, E. Ozcebe, O.I. Ozerkan, K. Ozturk, A. Papatryfonos, A. Parker, J.E. Pastore, M. Patrone, F. Patton, N. Pejin, D. Peñarrubia, M.J. Equiza, E.P. Peschel, C. Pession, A. Pigaditou, A. Pignon, B. Pihkala, U. Pimentel, P. Pitini, V. Podoltseva, E. Pogliani, E.M. Anna, A.P. Porta, F. Potter, M. Powles, R. Prentice, G.H. Pretnar, J. Ptushkin, V. Quarta, G. Reiter, A. Remes, K. Reykdal, S. Santasusana, J.M.R. Rifón, J. Rio, B. Rizzoli, V. Robak, T. Robinson, A.J. Rodeghiero, F. Rodríguez Fernández, J.M. Rombos, Y. Romeril, K.R. Rosenmayr, A. Rossi, J.F. Rosti, G. Rotoli, B. Rowe, J.M. Russell, N.H. Ryzhak, O. Rzepecki, P. Saglio, G. Salwender, H. Samonigg, H. Santoro, A. Sanz, M.A. Sayer, H.G. Scanni, A. Schaafsma, M.R. Schaefer, U.W. Schanz, U. Schattenberg, A. Schey, S.A.M. Schlimok, G. Schmoll, H.-J. Schots, R. Schouten, H. Schwarer, A.P. Schwerdtfeger, R. Scimè, R. Segel, E. Seger, R. Selleslag, D. Serban, M. Shamaa, S. Shaw, P.J. Siegert, W. Siena, S. Sierra, J. Simonsson, B. Singer, C.R.J. Sirchia, G. Skotnicki, A.B. Slavin, S. Snowden, J. Sotto, J.J. Tanyeli, A. Tedeschi, L. Tidefelt, U. Tissot, J.-D. Tobler, A. Tomas, J.F. Torres, J.P. Torres, G.A. Touraine, J.-L. Trneny, M. Uderzo, C. Unal, E. Unal, A. Undar, L. Urban, C. Van den Berg, H. van Marwijk, K.M. Vellenga, E. Venturini, M. Verdonck, L.F. Veys, P. Vilardell, J. Vinante, O. Visani, G. Vitek, A. Vivancos, P. Volpe, E. Vora, A. Vorlicek, J. Vowels, M. Vujic, D. Wachowiak, J. Wagner, T. Wahlin, A. Walewski, J. Wandt, H. Weissinger, F. Wijermans, P.W. Wiktor-Jedrzejczak, W. Will, A.M. Woell, E. Wörmann, B. Yaniv, I. Yesilipek, M.A. Yilmaz, U. Yong, A. Zachée, P. Zambelli, A. Zander, A.R. Zintl, F. Zoumbos, N.C. The Acute Leukemia Working Party (ALWP) of the European Cooperative Group for Blood Marrow Transplantation (EBMT)
- Abstract
Several studies have compared bone marrow (BM) and peripheral blood (PB) as stem cell sources in patients receiving allografts, but the cell doses infused have not been considered, especially for BM. Using the ALWP/EBMT registry, we retrospectively studied 881 adult patients with acute myelocytic leukemia (AML), who received a non-T-depleted allogeneic BM (n = 515) or mobilized PB (n = 366) standard transplant, in first remission (CR1), from an HLA-identical sibling, over a 5-year period from January 1994. The BM cell dose ranged from 0.17 to 29 × 108/kg with a median of 2.7 × 108/kg. The PB cell dose ranged from 0.02 to 77 × 10 8/kg with a median of 9.3 × 108/kg. The median dose for patients receiving BM (2.7 × 108/kg) gave the greatest discrimination. In multivariate analyses, high-dose BM compared to PB was associated with lower transplant-related mortality (RR = 0.61; 95% CI, 0.39-0.98; P = .04), better leukemia-free survival (RR = 0.65; 95% CI, 0.46-0.91; P = .013), and better overall survival (RR = 0.64; 95% CI, 0.44-0. 92; P = .016). The present study in patients with AML receiving allografts in first remission indicates a better outcome with BM as compared to PB, when the dose of BM infused is rich. © 2003 by The American Society of Hematology.
- Published
- 2003
15. Outcome is worse in male compared to female de novo AML patients and can be improved with the use of granulocyte colony stimulating factor(G-CSF) during induction. Results of a randomized multicentric Trial(Turkish leukemia study group (TLG95-002)
- Author
-
Beksac, M, Ozcan, M, Tunali, A, Dundar, S, Bayik, M, Paydas, SA, Ali, R, and Çukurova Üniversitesi
- Abstract
44th Annual Meeting of the American-Society-of-Hematology -- DEC 06-10, 2002 -- PHILADELPHIA, PENNSYLVANIA WOS: 000179184801070 … Amer Soc Hematol
- Published
- 2002
16. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow
- Author
-
Gorin, N.C. Labopin, M. Rocha, V. Arcese, W. Beksac, M. Gluckman, E. Ringden, O. Ruutu, T. Reiffers, J. Bandini, G. Falda, M. Zikos, P. Willemze, R. Frassoni, F. Abecasis, M. Abráhamová, J. Afanassiev, B.V. Aglietta, M. Alabdulaaly, A. Aleinikova, O. Paolo Alessandrino, E. Al Shemmari, S.H. Amadori, D. Amadori, S. Amos, T. Andolina, M. Andreesen, R. Angelucci, E. Anhuf, J. Arnold, R. Arpaci, F. Attal, M. Azevedo, W. Azim, H.A. Baccarani, M. Bacigalupo, A. Barbui, T. Bargetzi, M. Barnard, D.L. Bartsch, H.H. Baruchel, A. Battista, C. Bay, J.-O. Bayik, M. Bazarbachi, A. Beguin, Y. López, J.L.B. Benedek, I. Benedetti, F. Bengala, C. Berrebi, A. Besalduch, J. Biesma, D. Biron, P. Björkholm, M. Blaise, D. Blesing, N.E. Boasson, M. Bobev, D. Boccadoro, M. Bolaman, Z. Boogaerts, M.A. Bordessoule, D. Bosi, A. Aida, B.S. Bourhis, J.H. Bourikas, G. Bowen, D.T. Bregni, M. Bries, G. Brinch, L. Brittain, D. Bron, D. Brune, M. Bullorsky, E.O. Bunjes, D. Burdach, S. Burnett, A.K. Buzyn, A. Caballero, D. Cagirgan, S. Cahn, J.-Y. Canepa, C.O. Cao, A. Carella, A.M. Carrera, F.D. Carret, A.-S. Cascinu, S. Castel, V. Caswell, M. Cavanna, L. Cetto, G.L. Chapuis, B. Chasty, R. Chen, Y.-C. Chisesi, T. Chopra, R. Chybicka, A. Clark, R.E. Colombat, P. Colovic, M.D. Constenla-Figueiras, M. Contreras, M. Contu, L. Cordonnier, C. Cornelissen, J.J. Cornish, J. Coser, P. Costa, N. Coze, C. Craddock, C. Crown, J. Culligan, D.J. Danova, M. Darbyshire, P.J. Davies, J.M. de Bock, R. de Pablos Gallego, J.M. De Prijck, B. de Revel, T. De Rossi, G. De Souza, C.A. Deb, G. Degos, L. Demuynck, H. Dervenoulas, I. Di Bartolomeo, P. Di Renzo, N. Diaz, M.A. Diehl, V. Diez-Martin, J.L. Dincer, S. Giorgio, D. Dmoszynska, A. Doelken, G. Peter, P.D. Dulley, F. Easow, J. Ebell, W. Efremidis, A. Ehninger, G. Eichler, H. Eimermacher, H. Enno, A. Errazquin, L. Aguado, J.E. Everaus, H. Fagioli, F. Fanin, R. Fassas, A. Fasth, A. Faulkner, L.B. Fauser, A.A. Feldman, L. Feremans, W. Ferhanoglu, B. Fernández, M.N. Fernánde and Gorin, N.C. Labopin, M. Rocha, V. Arcese, W. Beksac, M. Gluckman, E. Ringden, O. Ruutu, T. Reiffers, J. Bandini, G. Falda, M. Zikos, P. Willemze, R. Frassoni, F. Abecasis, M. Abráhamová, J. Afanassiev, B.V. Aglietta, M. Alabdulaaly, A. Aleinikova, O. Paolo Alessandrino, E. Al Shemmari, S.H. Amadori, D. Amadori, S. Amos, T. Andolina, M. Andreesen, R. Angelucci, E. Anhuf, J. Arnold, R. Arpaci, F. Attal, M. Azevedo, W. Azim, H.A. Baccarani, M. Bacigalupo, A. Barbui, T. Bargetzi, M. Barnard, D.L. Bartsch, H.H. Baruchel, A. Battista, C. Bay, J.-O. Bayik, M. Bazarbachi, A. Beguin, Y. López, J.L.B. Benedek, I. Benedetti, F. Bengala, C. Berrebi, A. Besalduch, J. Biesma, D. Biron, P. Björkholm, M. Blaise, D. Blesing, N.E. Boasson, M. Bobev, D. Boccadoro, M. Bolaman, Z. Boogaerts, M.A. Bordessoule, D. Bosi, A. Aida, B.S. Bourhis, J.H. Bourikas, G. Bowen, D.T. Bregni, M. Bries, G. Brinch, L. Brittain, D. Bron, D. Brune, M. Bullorsky, E.O. Bunjes, D. Burdach, S. Burnett, A.K. Buzyn, A. Caballero, D. Cagirgan, S. Cahn, J.-Y. Canepa, C.O. Cao, A. Carella, A.M. Carrera, F.D. Carret, A.-S. Cascinu, S. Castel, V. Caswell, M. Cavanna, L. Cetto, G.L. Chapuis, B. Chasty, R. Chen, Y.-C. Chisesi, T. Chopra, R. Chybicka, A. Clark, R.E. Colombat, P. Colovic, M.D. Constenla-Figueiras, M. Contreras, M. Contu, L. Cordonnier, C. Cornelissen, J.J. Cornish, J. Coser, P. Costa, N. Coze, C. Craddock, C. Crown, J. Culligan, D.J. Danova, M. Darbyshire, P.J. Davies, J.M. de Bock, R. de Pablos Gallego, J.M. De Prijck, B. de Revel, T. De Rossi, G. De Souza, C.A. Deb, G. Degos, L. Demuynck, H. Dervenoulas, I. Di Bartolomeo, P. Di Renzo, N. Diaz, M.A. Diehl, V. Diez-Martin, J.L. Dincer, S. Giorgio, D. Dmoszynska, A. Doelken, G. Peter, P.D. Dulley, F. Easow, J. Ebell, W. Efremidis, A. Ehninger, G. Eichler, H. Eimermacher, H. Enno, A. Errazquin, L. Aguado, J.E. Everaus, H. Fagioli, F. Fanin, R. Fassas, A. Fasth, A. Faulkner, L.B. Fauser, A.A. Feldman, L. Feremans, W. Ferhanoglu, B. Fernández, M.N. Fernánde
- Abstract
Several studies have compared bone marrow (BM) and peripheral blood (PB) as stem cell sources in patients receiving allografts, but the cell doses infused have not been considered, especially for BM. Using the ALWP/EBMT registry, we retrospectively studied 881 adult patients with acute myelocytic leukemia (AML), who received a non-T-depleted allogeneic BM (n = 515) or mobilized PB (n = 366) standard transplant, in first remission (CR1), from an HLA-identical sibling, over a 5-year period from January 1994. The BM cell dose ranged from 0.17 to 29 × 108/kg with a median of 2.7 × 108/kg. The PB cell dose ranged from 0.02 to 77 × 10 8/kg with a median of 9.3 × 108/kg. The median dose for patients receiving BM (2.7 × 108/kg) gave the greatest discrimination. In multivariate analyses, high-dose BM compared to PB was associated with lower transplant-related mortality (RR = 0.61; 95% CI, 0.39-0.98; P = .04), better leukemia-free survival (RR = 0.65; 95% CI, 0.46-0.91; P = .013), and better overall survival (RR = 0.64; 95% CI, 0.44-0. 92; P = .016). The present study in patients with AML receiving allografts in first remission indicates a better outcome with BM as compared to PB, when the dose of BM infused is rich. © 2003 by The American Society of Hematology.
- Published
- 2003
17. 893 RATE AND TYPE OF LIVER INJURY AFTER BMT MAY DEPEND ON THE CONDITIONING REGIMEN IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES
- Author
-
Alahdab, Y., primary, Aktas, B., additional, Kaygusuz, I., additional, Gunduz, F., additional, Kedrah, A., additional, Cetiner, M., additional, Tuglular, T., additional, Bayik, M., additional, Ozdogan, O., additional, and Tozun, N., additional
- Published
- 2008
- Full Text
- View/download PDF
18. Storage effects on the Cole-Cole parameters of erythrocyte suspensions
- Author
-
Sezdi, M, primary, Bayik, M, additional, and Ulgen, Y, additional
- Published
- 2006
- Full Text
- View/download PDF
19. Imatinib does not inhibit neutrophil oxidative burst function in patients with chronic myelogenous leukemia
- Author
-
Bizargity, P., primary, Adiguzel, C., additional, Ozilhan, G., additional, Bayik, M., additional, and Eksioglu-Demiralp, E., additional
- Published
- 2005
- Full Text
- View/download PDF
20. Double G0/G1Peak in the DNA Histogram of Aberrant Marker Positive Acute Leukemia Patients is Associated with a Poor Clinical Outcome
- Author
-
Ekşioğlu-demiralp, E., primary, Budak-alpdoğan, T., additional, AledoğAn, Ö., additional, Atalay, A., additional, Ratip, S., additional, öz, D., additional, Bayik, M., additional, and Akoglu, T., additional
- Published
- 1999
- Full Text
- View/download PDF
21. MPGN and HCV infection in Istanbul, Turkey
- Author
-
Lawrence, R., primary, Ozener, C., additional, Cobanoglu, M., additional, Sahin, N., additional, Akoglu, E., additional, and Bayik, M., additional
- Published
- 1996
- Full Text
- View/download PDF
22. Treatment of thrombotic thrombocytopenic purpura with defibrotid
- Author
-
Mahmut Bayik, M., primary, Akoglu, Tevfik, additional, Tuglular, Tulin Firatli, additional, Akoglu, Emel, additional, Tezal, Merin, additional, Ulutin, Orhan, additional, and Lawrence, Roger, additional
- Published
- 1993
- Full Text
- View/download PDF
23. Subcutaneous Nodules Caused byPseudomonas aeruginosa:Healing Without Incision and Drainage
- Author
-
Korten, V., primary, Gürbüz, O., additional, Firatli, T., additional, Bayik, M., additional, and Akoglu, T., additional
- Published
- 1992
- Full Text
- View/download PDF
24. Effects of Imatinib Mesylate on Renin--Angiotensin System (RAS) Activity During the Clinical Course of Chronic Myeloid Leukaemia.
- Author
-
SAYITOGLU, M., HAZNEDAROĞLU, I. C., HATIRNAZ, O., ERBILGIN, Y., AKSU, S., KOCA, E., ADIGUZEL, C., BAYIK, M., AKALIN, I., GÜLBAS, Z., AKAY, M., UNAL, A., KAYNAR, L., OVALI, E., YILMAZ, M., YENEREL, M., DAGDAS, S., OZET, G., AR, C., and AYDIN, Y.
- Published
- 2009
25. Double G[sub 0]/G[sub 1] Peak in the DNA Histogram of Aberrant Marker Positive Acute Leukemia...
- Author
-
Eksioglu-Demiralp, E., Budak-Alpdogan, T., Alpdogan, O., Atalay, A., Ratip, S., Oz, D., Bayik, M., and Akoglu, T.
- Subjects
BIOMARKERS ,ACUTE leukemia ,PATIENTS - Abstract
Investigates the relationship between aberrant marker expression and DNA ploidy in acute leukemia patients. Use of flow cytometric DNA analysis to observe anaploidy; Absence of correlation between marker expression and apoptosis; Use of DNA ploidy as a prognostic tool.
- Published
- 1999
26. Synchronous renal cell carcinoma and multiple myeloma: Report of two cases and review of the literature
- Author
-
MEHMET AKIF OZTURK, Dane F, Kaygusuz I, Asmaz O, Uzay A, Bayik M, and Ns, Turhal
- Subjects
Male ,Neoplasms, Multiple Primary ,Interleukin-6 ,Risk Factors ,Humans ,Middle Aged ,Multiple Myeloma ,Carcinoma, Renal Cell ,Kidney Neoplasms - Abstract
Coexistence of renal cell carcinoma (RCC) and multiple myeloma (MM) is an extremely rare condition. Appearance of synchronous RCC and MM was not reported independently so far. In this brief communication, we report 2 cases of synchronous RCC and MM, discuss common risk factors or pathogenetic mechanisms seen in either RCC or MM, point out the importance of IL-6 in this coexistence and provide some descriptive properties of all reported synchronous RCC and MM cases.
27. Normal pressure hydrocephalus associated with chronic alpha interferon treatment: A case report
- Author
-
Ratip, S., Budak-Alpdogan, T., Alpdogan, O., Cetiner, M., Karti, S., İlhan Elmaci, and Bayik, M.
28. Complete heart block in a neutropenic patient with invasive aspergillosis
- Author
-
Kaygusuz, I., Odabaşi, Z., Adigüzel, C., Noyan, F., Birtas, E., VOLKAN KORTEN, Tuǧlular, T. F., Çetiner, M., and Bayik, M.
29. Kisitli dilüsyon yöntemi ile CD34+ kordon kani hücrelerinden uzundönemli kültür-başlatan hücreler (UDK-BH) üretimi
- Author
-
Sema Aktas, Tulin Budak Alpdogan, Gulderen Yanikkaya Demirel, Mahmut Bayik, Demirel, G.Y., Budak-Alpdog¨an, T., Aktaş, S., Bayik, M., Yeditepe Üniversitesi, Demirel, GY, Budak-Alpdogan, T, Aktas, S, and Bayik, M
- Subjects
Chemokine ,lcsh:Internal medicine ,CD34 ,CFU assay ,Flow cytometry ,Limiting dilution ,medicine ,Clonogenic assay ,lcsh:RC31-1245 ,Stem cell ,medicine.diagnostic_test ,biology ,business.industry ,lcsh:RC633-647.5 ,Cord blood ,Hematology ,lcsh:Diseases of the blood and blood-forming organs ,cytometry ,limiting dilution ,Haematopoiesis ,medicine.anatomical_structure ,LTC-IC ,Cancer research ,biology.protein ,cord blood ,Bone marrow ,business ,Cytometry - Abstract
Even though much progress has been made in defining primitive hematologic cell phenotypes by using flow cytometry and clonogenic methods, the direct method for study of marrow repopulating cells still remains to be elusive. Long Term Culture-Initiating Cells (LTC-IC) are known as the most primitive human hematopoietic cells detectable by in vitro functional assays.In this study, LTC-IC with limiting dilution assay was used to evaluate repopulating potential of cord blood stem cells.CD34 selections from cord blood were completed succesfully with magnetic beads (73,64%±9,12). The average incidence of week 5 LTC-IC was 1: 1966 CD34+ cells (range 1261-2906).We found that number of LTC-IC obtained from CD34+ cord blood cells were relatively low in numbers when compared to previously reported bone marrow CD34+ cells. This may be due to the lack of some transcription and growth factors along with some cytokines and chemokines released by accessory cells which are necessary for proliferation of cord blood progenitor/stem cells and it presents an area of interest for further studies.AMAÇ: Akım hücre ölçer ve klonojenik yöntemler kullanımı ile öncül hematolojik hücre fenotiplerinin tanımlanmasında çok aşama kaydedilmiş olmasına rağmen, kemik iliğini yenileyen hücrelerin doğrudan bir yöntemle tanımlanması henüz mümkün olmamaktadır. Uzun Dönemli Kültür-Başlatan Hücreler (UDK-BH) in vitro fonksiyonel yöntemlerle saptanabilen en öncül insan hematopoietik hücreleridir. YÖNTEMLER: Bu araştırmada, kordon kanı kök hücrelerinin kemik iliğini yenileyen hücre yeteneğini ölçümlemek üzere kısıtlı dilüsyon ile UDK-BH yöntemi uygulanmıştır.Kordon kanından CD34+ hücrelerin seleksiyonu manyetik boncuklarla başarı ile gerçekleştirilmiştir (%73,64±9,12). UDK-BH’lerin 5. haftada ortalama görülme sıklığı 1: 1966 CD34+ hücredir (aralık: 1261-2906). SONUÇ: CD34+ kordon kanı hücrelerinden elde edilen UDK-BH sayısı daha önce yayınlarda bildirilen kemik iliği hücreleri değerlerinden daha düşük düzeyde saptanmıştır. Bu bulgunun proliferasyon için gerekli olan sinyal transkripsiyon molekülleri, büyüme faktörleri, kemokin ve sitokinlerin aksesuar hücreler tarafından salınarak ortamda olmamasına bağlı olduğu düşünülmüştür. Bu alanda gelecekte daha çok araştırma yapılması bilgilerimizin artmasını sağlayacaktır.
- Published
- 2010
30. Stage IV Hodgkin's Disease presenting with spinal epidural involvement and cauda equina compression as the initial manifestation: Case report
- Author
-
Mahmut Bayik, Adnan Giral, Cigdem Ataizi Celikel, Nevzat Gürmen, Nihat Kodalli, Ahmet Toprak, Tulin Budak Alpdogan, and Toprak A., Kodalli N., Alpdogan T., Giral A., Celikel Ç., Gurmen N., Bayik M.
- Subjects
Male ,Cauda Equina ,REHABİLİTASYON ,MALIGNANT LYMPHOMA ,Sağlık Bilimleri ,Clinical Medicine (MED) ,Nöroloji (klinik) ,Nöroloji ,Antineoplastic Combined Chemotherapy Protocols ,Physical Medicine and Rehabilitation ,cauda equina compression ,Back pain ,SPACE ,Klinik Tıp (MED) ,Fizik Tedavi, Spor Terapisi ve Rehabilitasyon ,Hodgkin's Disease ,Klinik Tıp ,medicine.diagnostic_test ,Life Sciences ,Cauda equina ,General Medicine ,Hodgkin Disease ,Magnetic Resonance Imaging ,Tıp ,medicine.anatomical_structure ,Neurology ,Medicine ,medicine.symptom ,MRI ,Adult ,REHABILITATION ,medicine.medical_specialty ,spinal epidural involvement ,Physical Therapy, Sports Therapy and Rehabilitation ,CLINICAL NEUROLOGY ,Fiziksel Tıp ve Rehabilitasyon ,Diagnosis, Differential ,Kayropraktik ,Central nervous system disease ,Lumbar ,Health Sciences ,Yaşam Bilimleri ,medicine ,Humans ,Myelography ,Neoplasm Staging ,KLİNİK NÖROLOJİ ,Internal Medicine Sciences ,business.industry ,Nerve Compression Syndromes ,Magnetic resonance imaging ,Dahili Tıp Bilimleri ,CLINICAL MEDICINE ,medicine.disease ,Lymphoma ,Surgery ,Rehabilitasyon ,Epidural Neoplasms ,Chiropractics ,Neurology (clinical) ,Differential diagnosis ,business ,Low Back Pain ,CORD COMPRESSION - Abstract
Hodgkin\"s disease very rarely presents clinically, initially with a paraspinal mass, but this should be considered in the differential diagnosis. A patient presenting with back pain was diagnosed to have Stage IV Hodgkin\"s disease. MRI revealed an extradural and intraspinal soft tissue mass with bone infiltration. The importance of MRI in the early evaluation of a paraspinal mass and in determining the extent of the disease is emphasized.
- Published
- 1997
- Full Text
- View/download PDF
31. The epithelial barrier theory and its associated diseases.
- Author
-
Sun N, Ogulur I, Mitamura Y, Yazici D, Pat Y, Bu X, Li M, Zhu X, Babayev H, Ardicli S, Ardicli O, D'Avino P, Kiykim A, Sokolowska M, van de Veen W, Weidmann L, Akdis D, Ozdemir BG, Brüggen MC, Biedermann L, Straumann A, Kreienbühl A, Guttman-Yassky E, Santos AF, Del Giacco S, Traidl-Hoffmann C, Jackson DJ, Wang DY, Lauerma A, Breiteneder H, Zhang L, O'Mahony L, Pfaar O, O'Hehir R, Eiwegger T, Fokkens WJ, Cabanillas B, Ozdemir C, Kistler W, Bayik M, Nadeau KC, Torres MJ, Akdis M, Jutel M, Agache I, and Akdis CA
- Subjects
- Humans, Animals, Inflammation immunology, Epithelium immunology, Disease Susceptibility, Genetic Predisposition to Disease, Dysbiosis
- Abstract
The prevalence of many chronic noncommunicable diseases has been steadily rising over the past six decades. During this time, over 350,000 new chemical substances have been introduced to the lives of humans. In recent years, the epithelial barrier theory came to light explaining the growing prevalence and exacerbations of these diseases worldwide. It attributes their onset to a functionally impaired epithelial barrier triggered by the toxicity of the exposed substances, associated with microbial dysbiosis, immune system activation, and inflammation. Diseases encompassed by the epithelial barrier theory share common features such as an increased prevalence after the 1960s or 2000s that cannot (solely) be accounted for by the emergence of improved diagnostic methods. Other common traits include epithelial barrier defects, microbial dysbiosis with loss of commensals and colonization of opportunistic pathogens, and circulating inflammatory cells and cytokines. In addition, practically unrelated diseases that fulfill these criteria have started to emerge as multimorbidities during the last decades. Here, we provide a comprehensive overview of diseases encompassed by the epithelial barrier theory and discuss evidence and similarities for their epidemiology, genetic susceptibility, epithelial barrier dysfunction, microbial dysbiosis, and tissue inflammation., (© 2024 The Author(s). Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
32. Atypical presentations of eosinophilic fasciitis.
- Author
-
Ergun T, Seckin D, Salman A, Ocak ES, Yucelten AD, Direskeneli H, Demirkesen C, Ekinci G, and Bayik M
- Subjects
- Adolescent, Biopsy, Needle, Diagnosis, Differential, Eosinophilia diagnosis, Eosinophilia drug therapy, Fasciitis diagnosis, Fasciitis drug therapy, Female, Follow-Up Studies, Humans, Immunohistochemistry, Lichen Sclerosus et Atrophicus diagnosis, Lichen Sclerosus et Atrophicus drug therapy, Male, Middle Aged, PUVA Therapy methods, Risk Assessment, Sampling Studies, Scleroderma, Localized diagnosis, Scleroderma, Localized drug therapy, Treatment Outcome, Adrenal Cortex Hormones administration & dosage, Echo-Planar Imaging methods, Eosinophilia pathology, Fasciitis pathology, Lichen Sclerosus et Atrophicus pathology, Scleroderma, Localized pathology
- Abstract
Eosinophilic fasciitis is an uncommon connective tissue disease that may mimic and overlap with other sclerosing disorders such as morphea and lichen sclerosus. Herein, we report four patients (two men and two women, aged 16-64 yeas) with eosinophilic fasciitis. There was overlap with both morphea and lichen sclerosus in 2 patients and with morphoea alone in 1 patient. Magnetic resonance imaging (MRI) was used for diagnosis in three patients and for assessing treatment response in one patient. Eosinophilic fasciitis may co-exist with morhoea and lichen sclerosus. In view of the overlapping clinical and histopathological features of these disorders, MRI may be helful in delineating the conditions by detecting involvement of fascia.
- Published
- 2016
- Full Text
- View/download PDF
33. Myelodysplastic syndrome with t(9;22)(p24;q11.2), a BCR-JAK2 fusion: case report and review of the literature.
- Author
-
Kantarcioglu B, Kaygusuz-Atagunduz I, Uzay A, Toptas T, Tuglular TF, and Bayik M
- Subjects
- Chromosomes, Human, Pair 22 metabolism, Chromosomes, Human, Pair 9 metabolism, Female, Humans, Janus Kinase 2 metabolism, Middle Aged, Myelodysplastic Syndromes metabolism, Oncogene Proteins, Fusion metabolism, Proto-Oncogene Proteins c-bcr metabolism, Chromosomes, Human, Pair 22 genetics, Chromosomes, Human, Pair 9 genetics, Janus Kinase 2 genetics, Myelodysplastic Syndromes genetics, Oncogene Proteins, Fusion genetics, Proto-Oncogene Proteins c-bcr genetics, Translocation, Genetic
- Abstract
The human JAK2 gene is mainly targeted by two types of genetic lesions that play roles in the pathogenesis of hematologic malignancies: intragenic mutations and chromosomal translocations. Chromosomal translocations of JAK2 are typically associated with myeloid or lymphoid malignancies with an aggressive course and poor outcome. Here we report a t(9;22)(p24;q11.2) translocation, in a MDS patient and review results associated with BCR-JAK2 fusion reported in the literature.
- Published
- 2015
- Full Text
- View/download PDF
34. Newly diagnosed breast cancer in a patient receiving imatinib mesylate.
- Author
-
Kaygusuz-Atagunduz I, Toptas T, Yumuk F, Firatli-Tuglular T, and Bayik M
- Subjects
- Antineoplastic Agents therapeutic use, Chemotherapy, Adjuvant, Female, Humans, Imatinib Mesylate therapeutic use, Mastectomy, Middle Aged, Neoplasm Metastasis, Protein-Tyrosine Kinases metabolism, Radiotherapy methods, Antineoplastic Agents adverse effects, Breast Neoplasms complications, Breast Neoplasms etiology, Imatinib Mesylate adverse effects, Leukemia, Myelogenous, Chronic, BCR-ABL Positive complications, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy
- Abstract
Imatinib mesylate is the standard treatment of chronic myeloid leukemia (CML). Despite imatinib is being used in the treatment of other malignancies as well, its potential role on de novo tumor growth is not known. Secondary malignancies are rarely seen in patients with CML and particularly in those receiving imatinib. Here, we present a CML patient taking imatinib therapy that was diagnosed to have breast cancer and received adjuvant chemo-and radiotherapy with imatinib. We tried to explain co-occurrence of these rare events by probable pathogenetic mechanisms.
- Published
- 2014
- Full Text
- View/download PDF
35. Bortezomib in patients with renal impairment.
- Author
-
Kaygusuz I, Toptas T, Aydin F, Uzay A, Firatli-Tuglular T, and Bayik M
- Subjects
- Aged, Antineoplastic Agents administration & dosage, Antineoplastic Agents adverse effects, Antineoplastic Agents pharmacokinetics, Boronic Acids pharmacokinetics, Bortezomib, Cytochrome P-450 Enzyme System metabolism, Diarrhea chemically induced, Female, Humans, Male, Middle Aged, Pyrazines pharmacokinetics, Retrospective Studies, Survival Analysis, Boronic Acids administration & dosage, Boronic Acids adverse effects, Multiple Myeloma drug therapy, Multiple Myeloma metabolism, Pyrazines administration & dosage, Pyrazines adverse effects, Renal Insufficiency metabolism
- Abstract
Renal failure is a common manifestation of multiple myeloma (MM). Bortezomib is primarily metabolized by cytochrome p450 isoforms. It also has a cytochrome-independent metabolism by excretion through the bile and kidney. Based on our observations, we aimed to explore the efficacy and toxicity profiles of bortezomib in 56 patients with MM, 24 of which had moderate to severe renal failure. Overall response and complete response, as well as very good partial response rates, were comparable between patients with normal renal functions and renal impairment. The median overall survivals for patients with estimated glomerular filtration rates of <60 and ≥60 ml/minute were similar. Although there was a tendency for shorter overall survival along lower estimated glomerular filtration rates, this difference did not reach a statistical significance. Overall and severe adverse events, and dose modification and treatment discontinuation rates were higher in patients with renal impairment. Patients with renal failure had more thrombocytopenia and diarrhea. While thrombocytopenia was mild to moderate and manageable, diarrhea, which led to serious adverse events, was more severe in patients with renal failure who received bortezomib as monotherapy. Bortezomib appears to be active; however, when used alone, it may cause more frequent and severe adverse events in patients with MM and renal failure.
- Published
- 2011
- Full Text
- View/download PDF
36. Short and long term effects of granulocyte colony-stimulating factor during induction therapy in acute myeloid leukemia patients younger than 65: results of a randomized multicenter phase III trial.
- Author
-
Beksac M, Ali R, Ozcelik T, Ozcan M, Ozcebe O, Bayik M, Paydas S, Buyukasik Y, Ilhan O, Ozkalemkas F, Gurman G, Uysal A, Akan H, Soydan EA, and Tunali A
- Subjects
- Adolescent, Adult, Aged, Female, Humans, Leukemia, Myeloid, Acute pathology, Male, Middle Aged, Neoplasm Recurrence, Local pathology, Neutropenia drug therapy, Remission Induction, Survival Rate, Time Factors, Treatment Outcome, Young Adult, Drug Resistance, Neoplasm drug effects, Granulocyte Colony-Stimulating Factor therapeutic use, Leukemia, Myeloid, Acute drug therapy, Neoplasm Recurrence, Local drug therapy
- Abstract
This prospective multicenter phase III clinical trial was designed to assess efficacy and safety of G-CSF as an adjunct to de novo AML remission induction therapy (www.clinicaltrials.gov. NCT00820976). Patients' characteristics were similar in both arms. G-CSF improved severity and duration of leukopenia. Three-year OS were similar (25.6 ± 5.1% vs. 31.8 ± 5.6%) in both arms except for patients with myeloblastic features. Significant factors for better survival were the use of G-CSF (p=0.049), female sex (p=0.05) and single induction cycle (p<0.001) in multivariate analysis. Female patients performed better than male patients. Better survival obtained among female AML patients needs to be validated within the context of cytogenetic analysis., (Copyright © 2010 Elsevier Ltd. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
37. Aberrant expression of c-met and HGF/c-met pathway provides survival advantage in B-chronic lymphocytic leukemia.
- Author
-
Eksioglu-Demiralp E, Akdeniz T, and Bayik M
- Subjects
- B-Lymphocytes drug effects, Case-Control Studies, Cell Adhesion, Cell Survival, Cells, Cultured, Female, Fetal Blood cytology, Hepatocyte Growth Factor metabolism, Hepatocyte Growth Factor pharmacology, Humans, Integrin alpha4 metabolism, Leukemia, Lymphocytic, Chronic, B-Cell metabolism, Male, Phosphatidylinositol 3-Kinases metabolism, Proto-Oncogene Proteins c-met metabolism, Signal Transduction, bcl-Associated Death Protein metabolism, bcl-X Protein metabolism, B-Lymphocytes metabolism, Hepatocyte Growth Factor blood, Leukemia, Lymphocytic, Chronic, B-Cell pathology, Proto-Oncogene Proteins c-met biosynthesis
- Abstract
Background: B-chronic lymphocytic leukemia (B-CLL) is characterized by accumulation of CD5(+) B lymphocytes. Decreased VLA-4 (Cd49d/CD29) and CD11a expression and defective adhesion in B-CLL have been previously shown, although there was no substantial data about its importance in immunobiology of B-CLL. The hepatocyte growth factor (HGF) receptor, c-met, plays a role in adhesion by acting on VLA-4. c-met and VLA-4 share crucial signaling molecules in cell survival. In this study, relationship between expressions of c-met and CD49d, CD11a, and additional common signaling molecules in B-CLL was investigated., Methods: White blood cells from 24 patients with CLL were studied by flow cytometry and/or western blotting prior to and after culturing with recombinant HGF. HGF level from sera was measured with a bead-based flow cytometric assay., Results: c-metα and c-metβ were expressed on B-CLL cells, while no expression was observed on normal donor CD19+ cells. This increase was inversely correlated with decreased expression of adhesion molecules. Serum level of HGF in B-CLL was found to be increased. In vitro experiments showed that HGF supported survival in B-CLL cells supporting the possible function of HGF/c-met pathway in B-CLL. Furthermore, expressions of critical signaling molecules shared by both VLA-4 and HGF/c-met systems including Bcl-XL, Akt, PI3K, and phospho-bad(136) following HGF stimulations of B-CLL cells have been found to be increased., Conclusion: Increased expression of c-met and HGF may bypass the importance of expression of critical adhesion molecules and support survival of B-CLL cells. c-met, being one of the surface tyrosine kinases, may serve as a target for future therapies in B-CLL meriting more attention., (Copyright © 2010 International Clinical Cytometry Society.)
- Published
- 2011
- Full Text
- View/download PDF
38. Precursor B cell lymphoblastic lymphoma presenting as a solitary bone tumor: a case report and review of the literature.
- Author
-
Kaygusuz I, Toptas T, Guven A, Firatli-Tuglular T, Tecimer T, and Bayik M
- Subjects
- Anti-Inflammatory Agents administration & dosage, Antineoplastic Combined Chemotherapy Protocols, Bone Neoplasms therapy, Cyclophosphamide administration & dosage, Doxorubicin administration & dosage, Female, Hematopoietic Stem Cell Transplantation, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Positron-Emission Tomography, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma therapy, Prednisone administration & dosage, Transplantation, Homologous, Treatment Outcome, Vincristine administration & dosage, Antineoplastic Agents administration & dosage, Bone Neoplasms diagnosis, Bone Neoplasms pathology, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma diagnosis, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma pathology
- Abstract
Precursor B cell lymphoblastic lymphoma (B-LBL) is quite uncommon and it usually manifests as an extranodal disease. Although B-LBL may present with bone involvement, it is a very rare manifestation of B-LBL as a primary solitary bone tumor. Here, we report a case of precursor B-LBL presenting with solitary bone tumor and a review of a total of seven adult patients reported previously in the literature. We described demographic and clinical characteristics of these patients with unique presentation and discussed treatment options. Unlike previous reports except one case, our patient underwent allogeneic stem cell transplantation (allo-SCT) due to refractory disease. She is alive without evidence of disease by the post-transplant 12th month. B-LBL has an aggressive clinical course in adult patients and allo-SCT may be the best treatment option.
- Published
- 2010
- Full Text
- View/download PDF
39. Expression and prognostic significance of Cox-2 and p-53 in Hodgkin lymphomas: a retrospective study.
- Author
-
Barisik NO, Bozkurt S, Gumus M, Kaygusuz I, Karadayi N, Bas E, Bayik M, and Tecimer T
- Subjects
- Adult, Chi-Square Distribution, Hodgkin Disease mortality, Hodgkin Disease pathology, Hodgkin Disease therapy, Humans, Immunohistochemistry, Kaplan-Meier Estimate, Neoplasm Staging, Prognosis, Reed-Sternberg Cells pathology, Retrospective Studies, Survival Rate, Time Factors, Biomarkers, Tumor analysis, Cyclooxygenase 2 analysis, Hodgkin Disease enzymology, Reed-Sternberg Cells enzymology, Tumor Suppressor Protein p53 analysis
- Abstract
Background: Cyclooxygenase (cox) is the rate-limiting enzyme, which catalyzes the conversion of arachidonic acid into prostaglandins and contributes to the inflammatory process. Cyclooxygenase-2 (cox-2), which is one of the two isoforms, plays a role in tumor progression and carcinogenesis. p53 contributes to apoptosis, DNA renewal and cell cycle. Studies concerning the relationship of cox-2 and p53 expressions and carcinogenesis are available, but the association between cox-2 and p53 in Hodgkin lymphoma (HL) is not exactly known.In our study, we examined the association of cox-2 and p53 expression, with age, stage, histopathological subtype, and survival in HL. We also examined correlation between cox-2 and p53 expression., Methods: Cox-2 and p53 expressions in Hodgkin-Reed Sternberg cells (HRS) were examined in 54 patients with HL depending on cox-2 expression, stained cases were classified as positive, and unstained cases as negative. Nuclear staining of HRS cells with p53 was evaluated as positive. The classifications of positivity were as follows: negative if<10%; (1+) if 10-25%; (2+) if 25-50%; (3+) if 50-75%, (4+) if >75%., Results: Cox-2 and p53 expressions were found in 49 (80%) and 29 (46%) patients, respectively. There were differences between histological subtypes according to cox-2 expression (p = 0.012). Mixed cellular (MC) and nodular sclerosing (NS) subtypes were seen most of the patients and cox-2 expression was evaluated mostly in the mixed cellular subtype.There were no statistically significant relationships between p53 and the histopathological subtypes; or between p53, cox-2 and the factors including stage, age and survival; or between p53 and cox-2 expression (p > 0.05)., Conclusion: Considering the significant relationship between the cox-2 expression and the subtypes of HL, cox-2 expression is higher in MC and NS subtypes. However the difference between these two subtypes was not significant. This submission must be advocated by studies with large series.
- Published
- 2010
- Full Text
- View/download PDF
40. Bortezomib: a new therapeutic option for POEMS syndrome.
- Author
-
Kaygusuz I, Tezcan H, Cetiner M, Kocakaya O, Uzay A, and Bayik M
- Subjects
- Bortezomib, Glycoproteins blood, Humans, Male, POEMS Syndrome blood, Remission Induction, Antineoplastic Agents administration & dosage, Boronic Acids administration & dosage, POEMS Syndrome drug therapy, Pyrazines administration & dosage
- Abstract
Objective: POEMS syndrome with its classical five findings (Polyneuropathy, Organomegaly, Endocrinopathy, M protein, and Skin changes) is a rare multisystem disease. Proinflammatory and proangiogenic cytokines play important roles in its pathogenesis. Treatment options are still debated., Methods: We present a 65-year-old man with POEMS syndrome who was successfully treated with bortezomib., Results: After seven cycles of this protocol, serum M protein level declined to normal range, and near-to-complete remission was achieved. His symptoms of polyneuropathy improved dramatically., Conclusion: Bortezomib may be an effective and safe therapeutic option for patients with POEMS syndrome.
- Published
- 2010
- Full Text
- View/download PDF
41. Synchronous renal cell carcinoma and multiple myeloma: report of two cases and review of the literature.
- Author
-
Ozturk MA, Dane F, Kaygusuz I, Asmaz O, Uzay A, Bayik M, and Turhal NS
- Subjects
- Carcinoma, Renal Cell epidemiology, Carcinoma, Renal Cell therapy, Humans, Interleukin-6 blood, Kidney Neoplasms epidemiology, Kidney Neoplasms therapy, Male, Middle Aged, Multiple Myeloma epidemiology, Multiple Myeloma therapy, Neoplasms, Multiple Primary epidemiology, Neoplasms, Multiple Primary therapy, Risk Factors, Carcinoma, Renal Cell diagnosis, Interleukin-6 metabolism, Kidney Neoplasms diagnosis, Multiple Myeloma diagnosis, Neoplasms, Multiple Primary diagnosis
- Abstract
Coexistence of renal cell carcinoma (RCC) and multiple myeloma (MM) is an extremely rare condition. Appearance of synchronous RCC and MM was not reported independently so far. In this brief communication, we report 2 cases of synchronous RCC and MM, discuss common risk factors or pathogenetic mechanisms seen in either RCC or MM, point out the importance of IL-6 in this coexistence and provide some descriptive properties of all reported synchronous RCC and MM cases.
- Published
- 2009
42. Human herpes virus 8-unrelated primary effusion lymphoma-like lymphoma: report of a rare case and review of the literature.
- Author
-
Adiguzel C, Bozkurt SU, Kaygusuz I, Uzay A, Tecimer T, and Bayik M
- Subjects
- Aged, 80 and over, Diagnosis, Differential, Herpesvirus 8, Human, Humans, Lymphoma, Primary Effusion diagnostic imaging, Lymphoma, Primary Effusion therapy, Lymphoma, Primary Effusion virology, Male, Paracentesis, Pleural Effusion, Malignant diagnostic imaging, Pleural Effusion, Malignant therapy, Pleural Effusion, Malignant virology, Pleurodesis, Prognosis, Radiography, Remission Induction, Tomography Scanners, X-Ray Computed, Lymphoma, Primary Effusion diagnosis, Neoplasm Regression, Spontaneous, Pleural Effusion, Malignant diagnosis
- Abstract
A rare case of human herpes virus 8-unrelated primary effusion lymphoma-like lymphoma: a report and review of the literature. APMIS 2009; 117:222-29. Primary effusion lymphoma (PEL) is a very rare type of lymphoma usually confined to the body cavities predominantly in immunosuppressed patients infected with human herpes virus 8 (HHV-8). The new term for HHV-8 independent PEL is HHV8-unrelated PEL-like lymphoma. We describe an 89-year-old human immunodeficiency virus (HIV)-negative male patient with HHV8-unrelated PEL-like lymphoma in the pleura. No hepatosplenomegaly or lymphadenopathy was detected. Chest radiography and computed tomography revealed right pleural effusion, but no evidence of tumor mass or lymph node enlargement. Cytological analysis of the pleural effusion revealed a high-grade lymphoma with round nuclei, prominent nucleoli and abundant cytoplasm with immunophenotypes positive for CD45, CD30, CD38, CD7 and CD71. Because of the advanced age, no chemotherapy was given. Effusion resolved spontaneously. One year after the diagnosis, a new pleural effusion developed at the left side. Following thoracentesis and pleurodesis, the patient remained in complete remission for 40 months. To date, 30 cases of HHV8-unrelated PEL-like lymphoma/HIV negative have been reported in the literature. The outcome of the HHV8-unrelated PEL-like lymphoma patients who were HIV negative seems to be better than HIV- and HHV-8-positive PEL.
- Published
- 2009
- Full Text
- View/download PDF
43. Hairy cell leukemia in father and son.
- Author
-
Cetiner M, Adigüzel C, Argon D, Ratip S, Eksioglu-Demiralp E, Tecimer T, and Bayik M
- Subjects
- Aged, Antineoplastic Agents therapeutic use, Cladribine therapeutic use, Haplotypes, Humans, Interferon-alpha therapeutic use, Leukemia, Hairy Cell drug therapy, Leukemia, Hairy Cell pathology, Male, Middle Aged, Leukemia, Hairy Cell genetics
- Abstract
Hairy cell leukemia (HCL) is an uncommon B cell disorder, and familial HCL is rarely encountered among the first degree relatives of HCL patients. A father and son, both of whom developed hairy cell leukemia, is presented in this report. The HLA haplotype shared by the father and son was A2, B18, BW6, CW7, DR3, DR10, and DQ8. Among these haplotypes, HLA A2 and Bw6 have previously been reported.
- Published
- 2003
- Full Text
- View/download PDF
44. Effect of interferon-alpha(2a) on neutrophil adhesion and phagocytosis in chronic myeloid leukemia and Behçet's disease.
- Author
-
Kartí SS, Ovalí E, Ratip S, Cetiner M, Direskeneli H, Bayik M, and Akoğlu T
- Subjects
- Adult, Cell Adhesion drug effects, Dose-Response Relationship, Drug, Female, Humans, Interferon alpha-2, Male, Middle Aged, Recombinant Proteins, Reference Values, Antineoplastic Agents adverse effects, Behcet Syndrome blood, Interferon-alpha adverse effects, Leukemia, Myelogenous, Chronic, BCR-ABL Positive blood, Neutrophils physiology, Phagocytosis drug effects
- Abstract
Alpha-interferon (alpha-IFN) is implicated in a Behçet's disease (BD)-like syndrome observed in a small number of chronic myeloid leukemia (CML) patients. The effect of alpha-IFN on neutrophil adhesion and phagocytosis in CML patients, BD patients and healthy volunteers was investigated to clarify the reason for this observation. Ten subjects were studied for each group by incubating neutrophils with various doses of alpha-IFN. Basal neutrophil adhesions for CML patients, BD patients and healthy volunteers were similar. However, BD patients had greater basal phagocytosis than CML patients, and both groups had greater basal phagocytosis than healthy volunteers. Neutrophil adhesion and phagocytosis of CML patients increased following incubation with higher doses of alpha-IFN, and phagocytosis approached the high levels observed with BD neutrophils. This study provides evidence that alpha-IFN activates neutrophils in CML patients in a dose-dependent manner, and leads to a neutrophil function profile that resembles BD.
- Published
- 2002
- Full Text
- View/download PDF
45. Role of hepatocyte growth factor in the development of dendritic cells from CD34+ bone marrow cells.
- Author
-
Ovali E, Ratip S, Kibaroglu A, Tekelioglu Y, Cetiner M, Karti S, Aydin F, Bayik M, and Akoglu T
- Subjects
- Antigens, CD metabolism, Bone Marrow Cells drug effects, Flow Cytometry, Granulocyte-Macrophage Colony-Stimulating Factor pharmacology, Hepatocyte Growth Factor pharmacology, Humans, Lymphocyte Culture Test, Mixed, Time Factors, Tumor Necrosis Factor-alpha pharmacology, Antigens, CD34 analysis, Bone Marrow Cells cytology, Bone Marrow Cells immunology, Cell Differentiation drug effects, Dendritic Cells cytology, Hepatocyte Growth Factor physiology
- Abstract
Background and Objective: Hepatocyte growth factor (HGF) is known to augment the effects of stem cell factor, interleukin-3, granulocyte-macrophage colony-stimulating factor (GM-CSF), erythropoetin, and granulocyte colony-stimulating factor, all of which are involved in hematopoiesis. HGF is also known to have a role in immune responses. The aim of this study was to investigate whether HGF is involved in the development of dendritic cells (DC) from CD34+ bone marrow cells., Design and Methods: CD34+ cells obtained from three healthy donors were incubated in various combinations of HGF, GM-CSF, and tumor necrosis factor (TNF) for 12 days. Developing cell populations were analyzed for surface markers, morphology and functional capacities by flow cytometry, light microscopy and mixed lymphocyte reaction, respectively., Results: Incubation with HGF alone generated greater number of dendritic cells from CD34+ bone marrow cells than incubation with GM-CSF, or a combination of GM-CSF with TNF. HGF was also found to potentiate the effect of GM-CSF on DC and monocyte development. The effects of HGF were inhibited by the concurrent use of TNF., Interpretation and Conclusions: HGF appears to be a significant factor in the development of dendritic cells from CD34+ bone marrow cells.
- Published
- 2000
46. Double G0/G1 peak in the DNA histogram of aberrant marker positive acute leukemia patients is associated with a poor clinical outcome.
- Author
-
Ekşioğlu-Demiralp E, Budak-Alpdoğan T, Alpdoğan O, Atalay A, Ratip S, Oz D, Bayik M, and Akoğlu T
- Subjects
- Acute Disease, Adolescent, Adult, G1 Phase, Humans, Leukemia pathology, Leukemia physiopathology, Middle Aged, Predictive Value of Tests, Prognosis, Resting Phase, Cell Cycle, Aneuploidy, Biomarkers, Tumor, DNA, Neoplasm genetics, Leukemia genetics
- Abstract
In order to investigate the relationship between aberrant marker expression and DNA ploidy, 61 adult patients with acute leukemia (39 AML and 22 ALL) were studied. Aberrant marker expression was observed in 20 patients (16/39 of AML and 4/22 of ALL patients). In flow cytometric DNA analysis aneuploidy was observed in 18 patients (9/39 of AML and 9/22 of ALL patients). The incidence of aneuploidy in patients with aberrant marker expression was 35% whereas this was 26.8% in patients without aberrant marker expression. Furthermore, 7 patients with aberrant marker expression showed an aneuploid, double G0/G1 peaks appearance whereas the remaining 11 patients with aberrant marker expression had euploid DNA content. Double G0/G1 appearance was not observed in patients without aberrant marker expression. Further analyses revealed that this did not correlate with apoptosis. All 7 patients, who had both aberrant marker expression and double G0/G1 peak had a poor clinical outcome with a short survival and all died within three months whereas three-months survival was 67% for AML, 69% for ALL patients and 81% for patients with aberrant marker expression respectively (p<0.01). Our data indicate that the evaluation of the DNA ploidy in patients with aberrant marker expression may be of prognostic importance.
- Published
- 1999
- Full Text
- View/download PDF
47. Efficacy of high-dose methylprednisolone as a first-line therapy in adult patients with idiopathic thrombocytopenic purpura.
- Author
-
Alpdogan O, Budak-Alpdogan T, Ratip S, Firatli-Tuglular T, Tanriverdi S, Karti S, Bayik M, and Akoglu T
- Subjects
- Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Prednisolone therapeutic use, Glucocorticoids administration & dosage, Methylprednisolone administration & dosage, Purpura, Thrombocytopenic, Idiopathic drug therapy
- Abstract
Fifty-seven adult patients with idiopathic thrombocytopenic purpura (ITP) were treated with either conventional-dose prednisolone (CDP) (1 mg/kg/d, 36 patients) or high-dose methylprednisolone (HDP) (30 mg/kg/d, 21 patients), as first-line treatment. Patients in the HDP arm responded more rapidly (4.7 v 8.4 d), with a higher response rate (80% v 52.7%), and without severe side-effects. One quarter of the patients (3/12) who were non-responsive to CDP achieved complete remission when they were treated with HDP. The findings suggest that HDP may be a more effective first-line treatment than CDP for adult ITP, and it may also be preferred for life-threatening cases of ITP. However, these results must be confirmed by a randomized study prior to any change in the current practice of employing CDP as first-line treatment for adult ITP.
- Published
- 1998
- Full Text
- View/download PDF
48. Magnetic resonance imaging in myelofibrosis.
- Author
-
Alpdoğan O, Budak-Alpdoğan T, Bayik M, Akoğlu T, Kodalli N, and Gürmen N
- Subjects
- Adult, Aged, Bone Marrow pathology, Diagnosis, Differential, Disease Progression, Evaluation Studies as Topic, Female, Humans, Male, Middle Aged, Primary Myelofibrosis diagnosis, Primary Myelofibrosis mortality, Prognosis, Magnetic Resonance Imaging, Primary Myelofibrosis pathology
- Published
- 1998
49. Chemotherapy-induced acral erythema in leukemic patients: a report of 15 cases.
- Author
-
Demirçay Z, Gürbüz O, Alpdoğan TB, Yücelten D, Alpdoğan O, Kurtkaya O, and Bayik M
- Subjects
- Adolescent, Adult, Aged, Antibiotics, Antineoplastic adverse effects, Antibiotics, Antineoplastic therapeutic use, Antimetabolites, Antineoplastic adverse effects, Antimetabolites, Antineoplastic therapeutic use, Cytarabine adverse effects, Cytarabine therapeutic use, Daunorubicin adverse effects, Daunorubicin therapeutic use, Doxorubicin adverse effects, Doxorubicin therapeutic use, Erythema pathology, Female, Humans, Immunosuppressive Agents adverse effects, Immunosuppressive Agents therapeutic use, Leukemia, Myelogenous, Chronic, BCR-ABL Positive complications, Leukemia, Myeloid, Acute complications, Male, Middle Aged, Prospective Studies, Recurrence, Antineoplastic Combined Chemotherapy Protocols adverse effects, Erythema chemically induced, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Leukemia, Myeloid, Acute drug therapy
- Abstract
Background: Chemotherapy-induced acral erythema is a distinct localized cutaneous response to certain systemic chemotherapeutic agents., Methods: Between January 1990 and December 1994, from a total of 76 leukemic patients who have received combination chemotherapy consisting of cytosine arabinoside and anthracycline antibiotics, 15 patients developed chemotherapy-induced acral erythema. Fourteen of the patients had acute myelocytic leukemia, and one of them had chronic myelogenous leukemia in blast phase. Clinical features of these 15 patients have been analysed. Biopsy specimens obtained from eight of the patients were also evaluated for histopathologic alterations., Results: The overall incidence of this reaction was found to be 19.7% in our group of patients receiving this chemotherapy protocol. The onset of reaction varied from the fourth to the seventeenth days of the chemotherapy and resolved within 2 weeks in most of the patients. Lesions appeared as well-defined erythema and edema involving the palmar surfaces in all of the patients. In nine of the patients the reaction recurred with subsequent chemotherapies. Scattered necrotic keratinocytes, vacuolar alterations of the basal layer, and mild to moderate perivascular lymphocytic infiltration in the dermis were the histopathologic findings observed in the biopsy specimens., Conclusions: Chemotherapy-induced acral erythema is a frequent reaction in patients who are receiving high-dose chemotherapy. For patients in whom this self-limited condition develops, reassurance is the mainstay of therapy. Awareness of this reaction is also important to be able to differentiate it from acute graft versus host disease in patients who receive bone marrow transplants.
- Published
- 1997
- Full Text
- View/download PDF
50. Nephrotic syndrome associated with alpha interferon therapy in chronic myeloid leukemia.
- Author
-
Budak-Alpdoğan T, Lawrence RA, Bayik M, and Akoğlu E
- Subjects
- Antineoplastic Agents therapeutic use, Humans, Interferon-alpha therapeutic use, Male, Middle Aged, Antineoplastic Agents adverse effects, Interferon-alpha adverse effects, Leukemia, Myelogenous, Chronic, BCR-ABL Positive therapy, Nephrotic Syndrome etiology
- Published
- 1997
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.